Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider IJ, Corbacioglu A, Gaidzik VI, Meid A Dr, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf GG, Salwender HJ, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol FR, Heuser M, Ganser A, Döhner H, Döhner K.
Rücker FG, et al. Among authors: gotze ks.
Blood Adv. 2024 Sep 30:bloodadvances.2024013758. doi: 10.1182/bloodadvances.2024013758. Online ahead of print.
Blood Adv. 2024.
PMID: 39348668